Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients with advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial, named FIGHT, represents a significant milestone in the development of targeted therapies for these challenging cancers. The FIGHT […]